Major Thalasemia. Beta thalassemia
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive amlodipine at a dose of 5 to 2.5 mg with chelator for one year. After one week of treatment with amlodipine, the dose will increase to 5 mg. I
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. All patients had informed consent to participate in the study. 2- All thalassemia major patients referring to Amir Kabir Hospital, Arak, over 5 years old. .3. All healthy children without any underlying hematologic or hereditary diseases except major thalassemia
Exclusion criteria
Exclusion criteria: All patients who did not have informed consent to participate and continue to participate in the study. All patients who will undergo a chelation therapy strategy during the 12 months of study due to changes. All patients with advanced heart failure or Ef less than 30% or AV block All patients with MRI contraindication All patients with liver disorders, hepatitis B and C, HIV, any inflammation and renal failure All patients who have complications with amlodipine include edema, hypotension, palpitations, etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac iron overload. Timepoint: Will be measured at baseline and 12 months after treatment. Method of measurement: T2*MRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Ferritin serum level. Timepoint: At baseline and 1, 6, 12 months after treatment. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Vakilipour
Arak University of Medical Sciences
Outcome results
None listed